The momentum has broken badly and has a high PE. But he entered this on a rebound that has momentum. Despite an upgrade today, he doesn't see a green light ahead.
Stock price when the opinion was issued
As of Sep 03, 2026. Market Open.
Projected 19% earnings growth in 2026, yet trades at under 12x PE 2026. Has a robust drug pipeline.
Build your watch list
Sign in to track investmentsyou care about
Black Swan Dexteritas
Stockchase Premium
Stockchase
CNBC
iA Global Asset Management
The momentum has broken badly and has a high PE. But he entered this on a rebound that has momentum. Despite an upgrade today, he doesn't see a green light ahead.